Follow
Josée Zijlstra
Josée Zijlstra
Associate Professor of Hematology, VU University Medical Center, Amsterdam
Verified email at vumc.nl
Title
Cited by
Cited by
Year
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
R Boellaard, R Delgado-Bolton, WJG Oyen, F Giammarile, K Tatsch, ...
European journal of nuclear medicine and molecular imaging 42 (2), 328-354, 2015
21522015
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ...
Journal of clinical oncology 25 (5), 571-578, 2007
15922007
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
R Boellaard, MJ O’Doherty, WA Weber, FM Mottaghy, MN Lonsdale, ...
European journal of nuclear medicine and molecular imaging 37 (1), 181-200, 2010
14572010
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
A Engert, H Haverkamp, C Kobe, J Markova, C Renner, A Ho, J Zijlstra, ...
The Lancet 379 (9828), 1791-1799, 2012
6782012
Treatment of older patients with mantle-cell lymphoma
HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ...
New England Journal of Medicine 367 (6), 520-531, 2012
5782012
Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma
M Schaapveld, BMP Aleman, AM van Eggermond, CPM Janus, ADG Krol, ...
New England Journal of Medicine 373 (26), 2499-2511, 2015
5012015
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
R Boellaard, WJG Oyen, CJ Hoekstra, OS Hoekstra, EP Visser, ...
European journal of nuclear medicine and molecular imaging 35 (12), 2320-2333, 2008
4162008
Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes
ML De Bruin, J Sparidans, MB van't Veer, EM Noordijk, MWJ Louwman, ...
Journal of Clinical oncology 27 (26), 4239-4246, 2009
3832009
Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
B Von Tresckow, A Plutschow, M Fuchs, B Klimm, J Markova, A Lohri, ...
J Clin Oncol 30 (9), 907-913, 2012
3502012
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin …
P Borchmann, H Goergen, C Kobe, A Lohri, R Greil, DA Eichenauer, ...
The Lancet 390 (10114), 2790-2802, 2017
2892017
18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review
JM Zijlstra, G Lindauer-van der Werf, OS Hoekstra, L Hooft, PC Huijgens
Haematologica 91 (4), 522-529, 2006
2742006
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced …
C Kobe, M Dietlein, J Franklin, J Markova, A Lohri, H Amthauer, ...
Blood, The Journal of the American Society of Hematology 112 (10), 3989-3994, 2008
2532008
Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review
JC Regelink, MC Minnema, E Terpos, MH Kamphuis, PG Raijmakers, ...
British journal of haematology 162 (1), 50-61, 2013
2262013
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial
E Vellenga, WLJ van Putten, MB van't Veer, JM Zijlstra, WE Fibbe, ...
Blood, The Journal of the American Society of Hematology 111 (2), 537-543, 2008
2152008
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non …
K Behringer, H Goergen, F Hitz, JM Zijlstra, R Greil, J Markova, S Sasse, ...
The Lancet 385 (9976), 1418-1427, 2015
1902015
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
LR Perk, OJ Visser, M Stigter-van Walsum, MJWD Vosjan, GWM Visser, ...
European journal of nuclear medicine and molecular imaging 33 (11), 1337-1345, 2006
1812006
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ...
The Lancet Haematology 7 (7), e511-e522, 2020
1732020
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
BW Schot, JM Zijlstra, WJ Sluiter, GW van Imhoff, J Pruim, W Vaalburg, ...
Blood 109 (2), 486-491, 2007
1612007
Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials?
YWS Jauw, CW Menke-van der Houven van Oordt, OS Hoekstra, ...
Frontiers in pharmacology 7, 131, 2016
1442016
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
JEC Bromberg, S Issa, K Bakunina, MC Minnema, T Seute, M Durian, ...
The Lancet Oncology 20 (2), 216-228, 2019
1432019
The system can't perform the operation now. Try again later.
Articles 1–20